Early Detection of Cancer By Affinity Mass Spectrometry

东弗吉尼亚医学院(EVMS)生物标记物开发实验室(早期检测研究网络(EDRN)的成员)是一个综合的多学科项目，研究人员使用质谱仪技术挖掘蛋白质组，寻找独特的癌症生物标志物和蛋白质表达指纹，可用于改进前列腺癌、乳腺癌和头颈癌的早期检测。作为EDRN的成员，EVMS自成立以来，在应用新的蛋白质组学工具来检测肿瘤的表型特征和/或肿瘤环境方面做出了重大努力，为癌症的早期检测和风险评估寻找蛋白质生物标志物。在接下来的五年里，EVMS调查小组将继续独立和合作追求以下目标 与其他网络合作伙伴和以行业为基础的科学家。总体目标将通过三个目标实现；1)确定蛋白质图谱作为诊断试验的临床实用性；发现用于癌症早期检测的蛋白质生物标志物；以及分离和鉴定蛋白质生物标志物。在第一个目标中，我们将继续开发SELDI图谱作为前列腺癌和头颈癌的诊断工具。我们还描述了我们通过改进的峰值选择和数据分析方法来显著改进这一平台的研究，并描述了用于发现生物标记物的新的蛋白质组学工具ClinProt UltraFlex(MALDI-TOF/TOF)。在第二个目标中，我们将检查体液和组织以寻找乳腺癌、前列腺癌和H&N癌的早期标记。在第三个目标中，我们描述了用于早期检测和风险评估的候选生物标记物的序列识别和表征的方法。我们独特的团队 来自基础科学、数学科学和临床领域的研究人员提供了必要的专业知识，以继续我们在生物标记物开发方面的工作。

The Eastern Virginia Medical School (EVMS) Biomarkers Developmental Laboratory (a member of the Early Detection Research Network or EDRN) is an integrated multidisciplinary program where investigators use mass spectrometry technology to mine the proteome for unique cancer biomarkers and protein expression fingerprints that can be used to improve the early detection of prostate, breast and head and neck cancers. As a member of the EDRN since its inception, EVMS has led significant efforts in the application of novel proteomic tools to examine the phenotypic traits of tumors and/or the tumor environment in search of protein biomarkers for the early detection and risk assessment of cancer. During the next five years, the EVMS team of investigators will continue to pursue the following aims independently and in collaboration with other network partners and industry-based scientists. The overall objectives will be met through three aims; 1.) determine the clinical utility of protein profiling as a diagnostic test; 2.) discover protein biomarkers for the early detection of cancer; and 3.) isolate and characterize protein biomarkers. In the first aim we will continue to develop SELDI profiling as a diagnostic tool for prostate and Head & Neck cancers. We also describe our studies to significantly improve this platform through improved peak picking and data analysis methods and we describe a novel proteomic tool, ClinProt UltraFlex (MALDI-TOF/TOF) for biomarker discovery. In the second aim we will examine body fluids and tissue for early markers of breast, prostate and H&N cancer. In the third aim we describe our approach to sequence identification and characterization of candidate biomarkers for early detection and risk assessment. Our unique team of investigators from basic sciences, mathematical sciences and the clinical arena supply the needed expertise to continue our work in biomarker development.